It has recently been suggested that the inges-tion of selective serotonin re-uptake inhibitors is associated with upper gastrointestinal bleeding.
SELECTIVE SEROTONIN RE-UPTAKE
INHIBITORS
It
has recently been suggested that the inges-tion of selective serotonin
re-uptake inhibitors is associated with upper gastrointestinal bleeding (de
Abajo, Garcia-Rodriguez and Montero, 1999). From a general practice research
database, 1651 cases of gastrointestinal bleeding were identified along with 10
000 controls matched for age, gender and year of identification. Current use of
selective serotonin re-uptake inhibitors or other antidepressants within 30
days before gastrointestinal bleeding was assessed. The use of selective
serotonin re-uptake inhibitors was identified in 3.1% of patients with upper
gastroin-testinal bleeding compared with 1% of controls. The relative risk was
unaffected by gender, age, dose or duration of treatment. The absolute risk of
upper gastrointestinal bleeding was estimated as one case per 8000
prescriptions or one case per 1300 users. The authors also reported that the
risk of upper gastrointestinal bleeding was greatly potentiated by the
concomitant use of NSAIDs and, to a lesser extent, low-dose aspirin (de Abajo,
Garcia-Rodriguez and Montero, 1999). Further studies using alterna-tive methods
to confirm these observations have been recommended (Po, 1999).
Related Topics
TH 2019 - 2023 pharmacy180.com; Developed by Therithal info.